Acquisition of drug resistance in endothelial cells by tumor-derived extracellular vesicles and cancer progression

Abstract

Angiogenesis by endothelial cells (ECs) is essential for tumor growth. Angiogenesis inhibitors are used in combination with anticancer drugs in many tumor types, but tumors eventually become resistant. Previously, the underlying mechanism for developing drug resistance was considered to be a change in the characteristics of tumor cells whereas ECs were thought to be genetically stable and do not contribute to drug resistance. However, tumor endothelial cells (TECs) have been shown to differ from normal endothelial cells (NECs) in that they exhibit chromosomal abnormalities, angiogenic potential, and drug resistance. Extracellular vesicles (EVs) secreted by tumor cells have recently attracted attention as a factor involved in the acquisition of such abnormalities. Various cells communicate with each other through EVs, and it has been reported that tumor-derived EVs act on other tumor cells or stromal cells to develop drug resistance. Drug-resistant tumor cells confer drug resistance to recipient cells by transporting mRNAs encoding ATP-binding cassette subfamily B member 1 (ABCB1) and ATP-binding cassette subfamily C member 1 (ABCC1) as well as miRNAs involved in signaling such as Akt, drug efflux transporters, and P-glycoprotein modulators via EVs. However, there are limited reports on the acquisition of drug resistance in ECs by tumor-derived EVs. Since drug resistance of ECs may induce tumor metastasis and support tumor cell proliferation, the mechanism underlying the development of resistance should be elucidated to find therapeutic application. This review provides insight into the acquisition of drug resistance in ECs via tumor EVs in the tumor microenvironment.

Keywords

Tumor endothelial cell / drug resistance / extracellular vesicles / miRNA

References

[1] Folkman J.Angiogenesis: an organizing principle for drug discovery?.Nat Rev Drug Discov2007;6:273-86

[2] Folkman J.Angiogenesis in cancer, vascular, rheumatoid and other disease.Nat Med1995;1:27-31

[3] Folkman J.Role of angiogenesis in tumor growth and metastasis.Semin Oncol2002;29:15-8

[4] Reymond N,Ridley AJ.Crossing the endothelial barrier during metastasis.Nat Rev Cancer2013;13:858-70

[5] Folkman J.Tumor angiogenesis: therapeutic implications.N Engl J Med1971;285:1182-6

[6] Ivy SP,Kaufman BM.An overview of small-molecule inhibitors of VEGFR signaling.Nat Rev Clin Oncol2009;6:569-79

[7] Viallard C.Tumor angiogenesis and vascular normalization: alternative therapeutic targets.Angiogenesis2017;20:409-26

[8] Jain RK.Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy.Nat Med2001;7:987-9

[9] Ohtsu A,Van Cutsem E.Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.J Clin Oncol2011;29:3968-76

[10] Burger RA.Experience with bevacizumab in the management of epithelial ovarian cancer.J Clin Oncol2007;25:2902-8

[11] Pasqualini R,McDonald DM.Probing the structural and molecular diversity of tumor vasculature.Trends Mol Med2002;8:563-71

[12] McDonald DM.Significance of blood vessel leakiness in cancer.Cancer Res2002;62:5381-5

[13] Fidler IJ.Angiogenic heterogeneity: regulation of neoplastic angiogenesis by the organ microenvironment.J Natl Cancer Inst2001;93:1040-1

[14] Muz B,Azab F.The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy.Hypoxia2015;3:83-92 PMCID:PMC5045092

[15] Kerbel RS.Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents.Bioessays1991;13:31-6

[16] Dean M,Bates S.Tumour stem cells and drug resistance.Nat Rev Cancer2005;5:275-84

[17] Casanovas O,Bergers G.Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.Cancer Cell2005;8:299-309

[18] Langenkamp E.Microvascular endothelial cell heterogeneity: general concepts and pharmacological consequences for anti-angiogenic therapy of cancer.Cell Tissue Res2009;335:205-22

[19] Hida K,Amin DN.Tumor-associated endothelial cells with cytogenetic abnormalities.Cancer Res2004;64:8249-55

[20] Akino T,Hida Y.Cytogenetic abnormalities of tumor-associated endothelial cells in human malignant tumors.Am J Pathol2009;175:2657-67 PMCID:PMC2789618

[21] Matsuda K,Hida Y.Isolated tumor endothelial cells maintain specific character during long-term culture.Biochem Biophys Res Commun2010;394:947-54

[22] Muraki C,Hida Y.Cyclooxygenase-2 inhibition causes antiangiogenic effects on tumor endothelial and vascular progenitor cells.Int J Cancer2012;130:59-70

[23] Kurosu T,Hida Y.HuR keeps an angiogenic switch on by stabilising mRNA of VEGF and COX-2 in tumour endothelium.Br J Cancer2011;104:819-29

[24] Maishi N,Hida Y.CXCR7: a novel tumor endothelial marker in renal cell carcinoma.Pathol Int2012;62:309-17

[25] Yanagiya M,Maishi N.Correlation between endothelial CXCR7 expression and clinicopathological factors in oral squamous cell carcinoma.Pathol Int2021;71:383-91

[26] Maishi N,Akiyama K.Tumour endothelial cells in high metastatic tumours promote metastasis via epigenetic dysregulation of biglycan.Sci Rep2016;6:28039

[27] Yamamoto K,Hida Y.Biglycan is a specific marker and an autocrine angiogenic factor of tumour endothelial cells.Br J Cancer2012;106:1214-23

[28] Cong L,Annan DA.Inhibition of stromal biglycan promotes normalization of the tumor microenvironment and enhances chemotherapeutic efficacy.Breast Cancer Res2021;23:51

[29] Osawa T,Akiyama K.Lysyl oxidase secreted by tumour endothelial cells promotes angiogenesis and metastasis.Br J Cancer2013;109:2237-47

[30] Tsumita T,Annan DAM.The oxidized-LDL/LOX-1 axis in tumor endothelial cells enhances metastasis by recruiting neutrophils and cancer cells.Int J Cancer2022;151:944-56

[31] Osawa T,Hida Y.Prostacyclin receptor in tumor endothelial cells promotes angiogenesis in an autocrine manner.Cancer Sci2012;103:1038-44

[32] Akiyama K,Hida Y.Tumor endothelial cells acquire drug resistance by MDR1 up-regulation via VEGF signaling in tumor microenvironment.Am J Pathol2012;180:1283-93

[33] Akiyama K,Ohga N.Inhibition of multidrug transporter in tumor endothelial cells enhances antiangiogenic effects of low-dose metronomic paclitaxel.Am J Pathol2015;185:572-80

[34] Kikuchi H,Annan DA.Chemotherapy-induced IL8 upregulates MDR1/ABCB1 in tumor blood vessels and results in unfavorable outcome.Cancer Res2020;80:2996-3008

[35] Naito H,Kidoya H.Endothelial side population cells contribute to tumor angiogenesis and antiangiogenic drug resistance.Cancer Res2016;76:3200-10

[36] Ohmura-Kakutani H,Maishi N.Identification of tumor endothelial cells with high aldehyde dehydrogenase activity and a highly angiogenic phenotype.PLoS One2014;9:e113910

[37] Bussolati B,Russo S,Camussi G.Altered angiogenesis and survival in human tumor-derived endothelial cells.FASEB J2003;17:1159-61

[38] Xiong YQ,Zhang W.Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells.Clin Cancer Res2009;15:4838-46

[39] Ohga N,Maishi N.Heterogeneity of tumor endothelial cells: comparison between tumor endothelial cells isolated from high- and low-metastatic tumors.Am J Pathol2012;180:1294-307

[40] Sheu BC,Cheng CY,Chang DY.Cytokine regulation networks in the cancer microenvironment.Front Biosci2008;13:6255-68

[41] Kondoh M,Akiyama K.Hypoxia-induced reactive oxygen species cause chromosomal abnormalities in endothelial cells in the tumor microenvironment.PLoS One2013;8:e80349

[42] Jeppesen DK,Franklin JL.Extracellular vesicles and nanoparticles: emerging complexities.Trends Cell Biol2023;33:667-81

[43] Valadi H,Bossios A,Lee JJ.Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells.Nat Cell Biol2007;9:654-9

[44] Todorova D,Lacroix R,Dignat-George F.Extracellular vesicles in angiogenesis.Circ Res2017;120:1658-73 PMCID:PMC5426696

[45] Raposo G.Extracellular vesicles: exosomes, microvesicles, and friends.J Cell Biol2013;200:373-83 PMCID:PMC3575529

[46] Chen J,Zhang T.Review on strategies and technologies for exosome isolation and purification.Front Bioeng Biotechnol2021;9:811971

[47] Théry C,Aikawa E.Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines.J Extracell Vesicles2018;7:1535750

[48] Forder A,Trejo Vazquez J.Emerging role of extracellular vesicles and cellular communication in metastasis.Cells2021;10:3429 PMCID:PMC8700460

[49] Bobrie A,Reyal F.Rab27a supports exosome-dependent and -independent mechanisms that modify the tumor microenvironment and can promote tumor progression.Cancer Res2012;72:4920-30

[50] Araki Y,Yoshida T.Osteosarcoma-derived small extracellular vesicles enhance tumor metastasis and suppress osteoclastogenesis by miR-146a-5p.Front Oncol2021;11:667109 PMCID:PMC8130824

[51] Fang T,Lv G.Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer.Nat Commun2018;9:191

[52] Ji Q,Sui H.Primary tumors release ITGBL1-rich extracellular vesicles to promote distal metastatic tumor growth through fibroblast-niche formation.Nat Commun2020;11:1211

[53] Tsutsui T,Kimura R.Glioma-derived extracellular vesicles promote tumor progression by conveying WT1.Carcinogenesis2020;41:1238-45

[54] Al-Nedawi K,Kerbel RS,Rak J.Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR.Proc Natl Acad Sci U S A2009;106:3794-9 PMCID:PMC2656159

[55] Treps L,Edmond S,Gavard J.Glioblastoma stem-like cells secrete the pro-angiogenic VEGF-A factor in extracellular vesicles.J Extracell Vesicles2017;6:1359479 PMCID:PMC5549846

[56] You Y,Chen J.Matrix metalloproteinase 13-containing exosomes promote nasopharyngeal carcinoma metastasis.Cancer Sci2015;106:1669-77

[57] Huang A,Li S.Exosomal transfer of vasorin expressed in hepatocellular carcinoma cells promotes migration of human umbilical vein endothelial cells.Int J Biol Sci2015;11:961-9

[58] Kosaka N,Hagiwara K,Takeshita F.Neutral sphingomyelinase 2 (nSMase2)-dependent exosomal transfer of angiogenic microRNAs regulate cancer cell metastasis.J Biol Chem2013;288:10849-59 PMCID:PMC3624465

[59] Tadokoro H,Ohyashiki K,Ohyashiki JH.Exosomes derived from hypoxic leukemia cells enhance tube formation in endothelial cells.J Biol Chem2013;288:34343-51 PMCID:PMC3843049

[60] Chen X,Zhang T.MiR-9 promotes tumorigenesis and angiogenesis and is activated by MYC and OCT4 in human glioma.J Exp Clin Cancer Res2019;38:99

[61] Kawamoto T,Akiyama K.Tumor-derived microvesicles induce proangiogenic phenotype in endothelial cells via endocytosis.PLoS One2012;7:e34045

[62] Zhou W,Min Y.Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis.Cancer Cell2014;25:501-15 PMCID:PMC4016197

[63] Zeng Z,Pan Y.Cancer-derived exosomal miR-25-3p promotes pre-metastatic niche formation by inducing vascular permeability and angiogenesis.Nat Commun2018;9:5395

[64] Tominaga N,Ono M.Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood-brain barrier.Nat Commun2015;6:6716 PMCID:PMC4396394

[65] Di Modica M,Sandri M.Breast cancer-secreted miR-939 downregulates VE-cadherin and destroys the barrier function of endothelial monolayers.Cancer Lett2017;384:94-100

[66] Hsu YL,Chang WA.Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1.Oncogene2017;36:4929-42

[67] Morimoto M,Tsumita T.miR-1246 in tumor extracellular vesicles promotes metastasis via increased tumor cell adhesion and endothelial cell barrier destruction.Front Oncol2023;13:973871 PMCID:PMC10130374

[68] Sharma A.Chemoresistance in cancer cells: exosomes as potential regulators of therapeutic tumor heterogeneity.Nanomedicine2017;12:2137-48

[69] Qin X,Zhou L.Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100-5p-dependent manner.Int J Nanomedicine2017;12:3721-33 PMCID:PMC5439933

[70] Schinkel AH.Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview.Adv Drug Deliv Rev2012;64:138-53

[71] Corcoran C,O’Brien K.Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes.PLoS One2012;7:e50999

[72] Lv M,Chen W.Exosomes mediate drug resistance transfer in MCF-7 breast cancer cells and a probable mechanism is delivery of P-glycoprotein.Tumour Biol2014;35:10773-9

[73] Lopes-Rodrigues V,Sousa D.Multidrug resistant tumour cells shed more microvesicle-like EVs and less exosomes than their drug-sensitive counterpart cells.Biochim Biophys Acta2016;1860:618-27

[74] Wang J,Cui M.Exosome is a mechanism of intercellular drug transfer: application of quantitative pharmacology.J Control Release2017;268:147-58 PMCID:PMC5722714

[75] Li R,Jiang K.Rab27B enhances drug resistance in hepatocellular carcinoma by promoting exosome-mediated drug efflux.Carcinogenesis2020;41:1583-91

[76] Khoo XH,Goh BH.Cisplatin-resistance in oral squamous cell carcinoma: regulation by tumor cell-derived extracellular vesicles.Cancers2019;11:1166

[77] Yamamoto T,Yamamoto Y,Hattori Y.SORT1/LAMP2-mediated extracellular vesicle secretion and cell adhesion are linked to lenalidomide resistance in multiple myeloma.Blood Adv2022;6:2480-95

[78] Torii C,Kawamoto T.miRNA-1246 in extracellular vesicles secreted from metastatic tumor induces drug resistance in tumor endothelial cells.Sci Rep2021;11:13502

[79] Dong YP,Jiang L.Tumor endothelial expression of P-glycoprotein upon microvesicular transfer of TrpC5 derived from adriamycin-resistant breast cancer cells.Biochem Biophys Res Commun2014;446:85-90

[80] Richards KE,Fishel ML,Littlepage LE.Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells.Oncogene2017;36:1770-8 PMCID:PMC5366272

[81] Wei K,Yang F.M2 macrophage-derived exosomes promote lung adenocarcinoma progression by delivering miR-942.Cancer Lett2022;526:205-16

[82] Ma T,Guo Y.Human umbilical vein endothelial cells-derived microRNA-203-containing extracellular vesicles alleviate non-small-cell lung cancer progression through modulating the DTL/p21 axis.Cancer Gene Ther2022;29:87-100

[83] Lombardo G,Togliatto G.Activated stat5 trafficking via endothelial cell-derived extracellular vesicles controls IL-3 pro-angiogenic paracrine action.Sci Rep2016;6:25689

[84] Lombardo G,Grange C.IL-3R-alpha blockade inhibits tumor endothelial cell-derived extracellular vesicle (EV)-mediated vessel formation by targeting the β-catenin pathway.Oncogene2018;37:1175-91 PMCID:PMC5861089

[85] Lopatina T,Cavallari C.Targeting IL-3Rα on tumor-derived endothelial cells blunts metastatic spread of triple-negative breast cancer via extracellular vesicle reprogramming.Oncogenesis2020;9:90

[86] Lopatina T,Danilova L.Extracellular vesicles released by tumor endothelial cells spread immunosuppressive and transforming signals through various recipient cells.Front Cell Dev Biol2020;8:698

[87] Nishida-Aoki N,Kosaka N.Altered biodistribution of deglycosylated extracellular vesicles through enhanced cellular uptake.J Extracell Vesicles2020;9:1713527 PMCID:PMC7006786

[88] Di Lernia G,Solimando AG.Bortezomib treatment modulates autophagy in multiple myeloma.J Clin Med2020;9:552